Research Program: Tumor Biology and Progression
Associate Professor, Department of Urologic Surgery

slato001@umn.edu
612-626-0964 — office
612-467-2890 — lab
Preferred method of contact: office phone

Dr. Slaton's clinical profile
(University of Minnesota Physicians Web site)

• Vanderbilt University, Nashville, TN; B.S, 1984, Chemistry
• Vanderbilt University, Nashville, TN; M.D, 1988, Medicine
• Medical College of Ohio, Toledo, OH; M.S.B.S, 1994, Urology

Research Interests

1. metastasis-related gene expression in urologic neoplasms pre-/post-treatment
2. tumor markers in superficial bladder cancer
3. development of nanoencapsulated tumor/histology specific mri agents
4. CK2 antisense targeting of prostate cancer

Selected Publications

Slaton, J.W., Dinney, C.P.N., Veltri, R. W., Miller, M. C., Liebert M., O'Dowd, G. J., and Grossman, H. B. DNA ploidy enhances the cytologic prediction of recurrent transitional cell carcinoma of the bladder. J. Urol. 158: 806-811, 1997.

Slaton, J.W., Balbay, M.D., Levy, D.A., Pisters, L.L., Nesbitt, J.C., Swanson, D.A and Dinney, C.P.N. Nephrectomy and vena caval thrombectomy in patients with metastatic renal cell carcinoma. Urology 50:673-677,1997

Slaton, J.W., Perrotte, P., Inoue, K., Dinney, C.P.N., and Fidler, I.J. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of dose and schedule. Clin Cancer Res 5:2726-34, 1999.

Balbay, M.D., Slaton, J. W., Trane, N.,Skibber, J., and Dinney, C. P. N. Rationale for bladder-sparing in patients with locally advanced rectal carcinoma. Cancer 86:2212-16, 1999.

Pettaway, C.A., Pisters, L.L., Finn, D., Slaton, J. W., and Logothetis, C.J. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: Feasibility and preliminary results. J Clin Oncol 18:1050, 2000.